Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors
- PMID: 16719786
- DOI: 10.2174/092986706776872907
Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors
Abstract
The present report provides a extended study of the chemistry, the inhibitory activity against monoamino oxidases (MAO), and molecular modeling including the 3D-QSAR hypothesis of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives. Four series of about eighty novel pyrazoline derivatives were prepared and investigated for their ability to inhibit the activity of the A and B isoforms of MAO selectively. Most of the new synthesized compounds proved more reversible, potent, and selective inhibitors of MAO-A than of MAO-B, and could be taken into account to develop the search further in this field, knowing that reversible and selective MAO-A inhibitors are used as antidepressant and antianxiety drug. The 30 most active compounds show inhibitory activity on MAO-A in the 8.6 x 10(-8) - 9.0 x 10(-9)M range. Moreover, it should be pointed out that for most of them a high IC(50) > or = 10(-9)M value is associated with a high A-selectivity (Selectivity Index MAO-B/MAO-A in the 10,000-16,250 range). Furthermore, due to the presence of a chiral centre at the C5 position of the pyrazole moiety, we performed the semi-preparative chromatographic enantioseparation of the most potent, selective, and chiral compounds. The separated enantiomers were then submitted to in vitro biological evaluation, and from the results of these experiments it has been possible to point out a difference in inhibiting the two isoforms selectively between the racemic mixture and the single enantiomers. The molecular modeling work was carried out combining the Glide docking approach with CoMFA with the aim to rationalize the structure-activity relationships of each pyrazoline inhibitor toward MAO-A and MAO-B isoforms and to derive a suitable selectivity model.
Similar articles
-
Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase.J Med Chem. 2004 Apr 8;47(8):2071-4. doi: 10.1021/jm031042b. J Med Chem. 2004. PMID: 15056004
-
Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives.J Med Chem. 2005 Nov 17;48(23):7113-22. doi: 10.1021/jm040903t. J Med Chem. 2005. PMID: 16279769
-
Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.Chem Biol Drug Des. 2006 Mar;67(3):206-14. doi: 10.1111/j.1747-0285.2006.00367.x. Chem Biol Drug Des. 2006. PMID: 16611214
-
Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors.Farmaco. 2003 Mar;58(3):231-41. doi: 10.1016/S0014-827X(03)00016-8. Farmaco. 2003. PMID: 12620419 Review.
-
Pyrazoline Derivatives as Promising MAO-A Targeting Antidepressants: An Update.Curr Top Med Chem. 2024;24(5):401-415. doi: 10.2174/0115680266280249240126052505. Curr Top Med Chem. 2024. PMID: 38318823 Review.
Cited by
-
Heterocyclic Compounds: Pharmacology of Pyrazole Analogs From Rational Structural Considerations.Front Pharmacol. 2021 May 10;12:666725. doi: 10.3389/fphar.2021.666725. eCollection 2021. Front Pharmacol. 2021. PMID: 34040529 Free PMC article. Review.
-
Predicting monoamine oxidase inhibitory activity through ligand-based models.Curr Top Med Chem. 2012;12(20):2258-74. doi: 10.2174/156802612805219987. Curr Top Med Chem. 2012. PMID: 23231398 Free PMC article. Review.
-
3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders.Sci Pharm. 2010 Apr-Jun;78(2):233-48. doi: 10.3797/scipharm.0912-22. Epub 2010 May 5. Sci Pharm. 2010. PMID: 21179345 Free PMC article.
-
Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders.ACS Omega. 2022 Oct 17;7(43):38207-38245. doi: 10.1021/acsomega.2c05339. eCollection 2022 Nov 1. ACS Omega. 2022. PMID: 36340076 Free PMC article. Review.
-
4-(2H-1,3-Benzodioxol-5-yl)-1-(4-methyl-phenyl)-1H-pyrazol-5-amine.Acta Crystallogr Sect E Struct Rep Online. 2013 Apr 17;69(Pt 5):o736-7. doi: 10.1107/S1600536813009914. Print 2013 May 1. Acta Crystallogr Sect E Struct Rep Online. 2013. PMID: 23723888 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous